BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
9/14/2016 7:04:00 PM | Browse: 1777 | Download: 3538
 |
Received |
|
2016-06-04 14:19 |
|
Peer-Review Started |
|
2016-06-05 09:58 |
 |
First Decision by Editorial Office Director |
|
|
|
Return for Revision |
|
2016-06-28 09:21 |
|
Revised |
|
2016-07-21 21:25 |
|
Publication Fee Transferred |
|
|
|
Second Decision by Editor |
|
2016-08-05 10:18 |
|
Second Decision by Editor-in-Chief |
|
|
|
Final Decision by Editorial Office Director |
|
2016-08-10 15:48 |
|
Articles in Press |
|
2016-08-10 15:48 |
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2016-09-01 14:21 |
|
Publish the Manuscript Online |
|
2016-09-14 19:04 |
| ISSN |
1007-9327 (print) and 2219-2840 (online) |
| Open Access |
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2016. Published by Baishideng Publishing Group Inc. All rights reserved.
|
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Gastroenterology & Hepatology |
| Manuscript Type |
Retrospective Cohort Study |
| Article Title |
Second-generation direct-acting-antiviral hepatitis C virus treatment: Efficacy, safety, and predictors of SVR12
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Christoph R Werner, Julia M Schwarz, Daniel P Egetemeyr, Robert Beck, Nisar P Malek, Ulrich M Lauer and Christoph P Berg |
| Funding Agency and Grant Number |
|
| Corresponding Author |
Christoph P Berg, MD, Department of Gastroenterology, Hepatology, and Infectiology, University Hospital Tübingen, Otfried-Müller-Str. 10, 72076 Tübingen, Germany. christoph.berg@med.uni-tuebingen.de
|
| Key Words |
Sofosbuvir; Simeprevir; Ledipasvir; Hepatitis C; Liver transplant; Sustained virological response; Liver cirrhosis; Side effects; Resistance; Daclatasvir |
| Core Tip |
From 2014 on the second wave of direct acting antiviral agents was available for treatment of chronic hepatitis C infection. Due to the more heterogeneous character of patients in the “real world”, the therapeutic performance of these new drugs outside randomized clinical trials is of interest. Therefore, in this monocentric retrospective cohort study, we analyzed the efficacy, safety, and predictors of sustained virological response 12 for treatment with combinations of second generation direct acting antivirals in a “real-world” setting.
|
| Publish Date |
2016-09-14 19:04 |
| Citation |
Werner CR, Schwarz JM, Egetemeyr DP, Beck R, Malek NP, Lauer UM, Berg CP. Second-generation direct-acting-antiviral hepatitis C virus treatment: Efficacy, safety, and predictors of SVR12. World J Gastroenterol 2016; 22(35): 8050-8059
|
| URL |
http://www.wjgnet.com/1007-9327/full/v22/i35/8050.htm |
| DOI |
http://dx.doi.org/10.3748/wjg.v22.i35.8050 |
Copyright © 1993-2026 Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA. All rights reserved, including rights relating to text and data mining, AI training, and similar technologies. For open-access content, the applicable copyright and licensing terms govern.
